Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Now 275,000 under .01. Not much but this needs a lot more volume.
I agree...just need another 1,940,000 shares LOL
YES. Even a little could spring it. 2 mil in volume brings it to .02 i think
Need some more buying...this is a major MOMO play.
Yes, have to be lightning quick w/ this one. LOL
Have some...grabbed a few as a lotto since it moves so easily. I'll set a GTC sell order in case I miss the next 30 minute run LOL.
Someone is buying here now anyway. Might be WOWZA!
Nah, because he was still pumping after at 007. He might have dumped at 006 or 007. Do you have any?
I doubt he is...he quit pumping it when it hit .014. My guess is that he dumped into the run.
You still holding this Wowza? This could easily go to 3 cents
YEs, I got a few as well. EAsy mover!
Hopefully we see news. I got some at .006, went to get a shower only to learn it ran to .014 and came down to .005. Khaaaaaaaaaaaaan!!! At least now we know that she moves very easy. News and it takes of like a bat from hell. IMO
Does anyone know something or are we just playing dominos with the great SS? =)
Hope not! 12 o/s and float should be under 10m looking very interesting here
Yeah I noticed the same.....been holding some dead shares for a while. Gonna try to contact the TA tomorrow and get the current SS....I'm assuming it's not gagged?
bought some today!! looks like something start cooking here!! this stock was $5.00 and o/s only 12m!! could be one can make us huge $$4
This one has been a major disappointment. Their conference calls back when they were in dollar land were well organized and it seemed that they had a quality product. Doubt this one will dead cat bounce though but what are your thoughts?
Good stuff thanks edurk
NMT Medical, Inc. will sell its BioTREK technology platform
, which has been assigned to Joseph F. Finn, Jr., C.P.A. ("Finn") of the firm Finn, Warnke & Gayton, LLP to be liquidated for the benefit of NMT Medical creditors, at its sealed bid sale of June 10, 2011.
BioTREK is a technology platform that utilizes a novel bioabsorbable polymer to create a family of percutaneous devices for repair or remodeling of intracardiac defects including patent foramen ovale (PFO), atrial septal defect (ASD) and left atrial appendage (LAA). Unlike other bioabsorbable cardiac implants, BioTREK implants are rendered radiopaque for fluoroscopic visualization using a proprietary technology developed by NMT Medical.
The intellectual property, patents, etc. will be sold at a sealed bid sale on Friday, June 10, 2011 at noon. Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's Office - jffinnjr@finnwarnkegayton.com or 781-237-8840. They will then receive a bid package.
http://www.otcmarkets.com/stock/NMTI/news
B-Money, Here is what I've been able to find, in answer to your questions.
__________________________________________________________________
In April they filed 4 Confidential treatment orders
there existing cash resources were not sufficient to fund business plans, as currently constituted, beyond the fourth quarter of 2010?
A: ORDER GRANTING CONFIDENTIAL TREATMENT
http://quotemedia.10kwizard.com/cgi/image?repo=tenk&ipage=7493141&action=PDF&doc=1
A: NOTIFICATION OF LATE FILING
As we reported in our quarterly filing on Form 10-Q for the quarter ended September 30, 2010, our existing cash resources were not sufficient to fund our business plans, as currently constituted, beyond the fourth quarter of 2010.
In response to this liquidity issue, the Company has streamlined its operations and significantly curtailed expenses while, at the same time, seeking sources of capital through potential debt and equity financings and/or strategic transactions including the potential sale of the Company.
The Company to date has not been able to raise additional debt or equity capital and has continued to explore its strategic options.
Although the Company's outside auditors commenced its audit with respect to the year ended December 31, 2010, the completion of the audit was postponed by us. The Company does not anticipate its outside auditors to complete the audit for the year ended December 31, 2010 unless deemed prudent by the Company to do so in light of the Company's strategic options. There can be no assurance that a strategic transaction will be consummated or that the Company will be able to engage an auditor of its financial statements for the year ended December 31, 2010.
http://app.quotemedia.com/quotetools/showFiling.go?webmasterId=101187&name=NMT%20MEDICAL%20INC:%20NT%2010-K,%20Sub-Doc%201,%20Page%201&link=http%3A//quotemedia.10kwizard.com/filing.xml%3Frid%3D23%26ipage%3D7518103%26DSEQ%3D1%26SQDESC%3DSECTION_BODY%26doc%3D1&cp=on
_________________________________________________________________
Q: You think they have loan in place?
A: I don't know
Q: Any luck verifying actual SS? As of November 5, 2010, there were 16,020,069 OS could not verify A/S?
A: Shares Outstanding = 16,020,069 as of Nov 05, 2010
http://www.otcmarkets.com/stock/NMTI/company-info
http://www.investorpoint.com/stock/NMTI-NMT%20Medical%20Inc./
In April they filed 4 Confidential treatment orders
there existing cash resources were not sufficient to fund business plans, as currently constituted, beyond the fourth quarter of 2010?
You think they have loan in place?
Any luck verifying actual SS? As of November 5, 2010, there were 16,020,069 OS could not verify A/S?
NMTI, Sealed Bid on IP, was June 10th.
Nice slope play !!
0.20c to 0.30c possible here !!!
NMT Medical, Inc. to Sell BioTREK Technology Platform at Its Sealed Bid Sale on Friday, June 10, 2011 at Twelve O'Clock Noon
http://www.otcmarkets.com/stock/NMTI/quote
http://stockcharts.com/h-sc/ui?s=NMTI&p=D&yr=1&mn=0&dy=0&id=p27000828142
http://barchart.com/chart.php?sym=NMTI&style=technical&p=DO&d=H&sd=&ed=&size=M&log=0&t=BAR&v=1&g=1&evnt=1&late=1&o1=&o2=&o3=&sh=100&indicators=MFI%2814%2C255%2C100%2C39168%2C16711680%29%3BSTOSL%2814%2C3%2C16763904%2C6724095%29%3BSMA%2820%2C16711680%29&chartindicator_4_code=MFI&chartindicator_4_param_0=14&chartindicator_4_param_1=255&chartindicator_4_param_2=100&chartindicator_4_param_3=39168&chartindicator_4_param_4=16711680&chartindicator_5_code=STOSL&chartindicator_5_param_0=14&chartindicator_5_param_1=3&chartindicator_5_param_2=16763904&chartindicator_5_param_3=6724095&chartindicator_6_code=SMA&chartindicator_6_param_0=20&chartindicator_6_param_1=16711680&addindicator=&submitted=1&fpage=&txtDate=&x=13&y=12
NMTI Update for Tuesday, June 14th
ALERTS
Top Bullish Divergence
Stochastic Oversold Reversal
Intermediate Term Bullish Breakout
http://www.stockta.com/cgi-bin/analysis.pl?symb=NMTI&table=trend&mode=table
http://stockcharts.com/h-sc/ui?s=NMTI&p=D&yr=1&mn=0&dy=0&id=p05917422241
http://www.investorpoint.com/stock/NMTI-NMT+Medical+Inc./chart/
Target Objectives:
0.19c to 0.24c
And, when the company gets around to releasing this 10-K that has been late, it could yield some very interesting NEWS that will catch a lot of people off-guard!!
It won't take much to lift this stock to higher levels with only having 16M S/O.
Bullish Divergence At-Hand Here
http://stockcharts.com/h-sc/ui?s=NMTI&p=D&yr=0&mn=6&dy=0&id=p04160800075
http://www.investorpoint.com/stock/NMTI-NMT+Medical+Inc./sec-filings/
Ameritrade indicates about 16M shares total for NMTI and looking at the volume for the last two months, I can not see where a majority of shares have been sold off (shares still being held ?). Also been watching trades for the last few months and noticed someone trying to keep the price down with small sells on most of the days. Maybe someone is eyeing this Company for takeover, in addition to beneficial use of possible NOLS ? With the auction being held today, it could be interesting the next few months to see what develops.
From the amount of board book marks and posting activity for this stock, not many have paid attention to this stock. Hopefully that will change soon.
NMTI Update for Friday June 10th
ALERTS
Top Bullish Divergence
rsi Over Sold Buried
Intermediate Term Bullish Breakout
http://www.stockta.com/cgi-bin/analysis.pl?symb=NMTI&table=trend&mode=table
http://stockcharts.com/h-sc/ui?s=NMTI&p=D&yr=1&mn=0&dy=0&id=p05917422241
http://www.investorpoint.com/stock/NMTI-NMT+Medical+Inc./chart/
Target Objectives:
0.19c to 0.24c
NMTI, Sealed Bid on IP, June 10th.
Nice slope play !!
0.20c to 0.30c possible here !!!
NMT Medical, Inc. to Sell BioTREK Technology Platform at Its Sealed Bid Sale on Friday, June 10, 2011 at Twelve O'Clock Noon
http://www.otcmarkets.com/stock/NMTI/quote
http://stockcharts.com/h-sc/ui?s=NMTI&p=D&yr=1&mn=0&dy=0&id=p27000828142
http://barchart.com/chart.php?sym=NMTI&style=technical&p=DO&d=H&sd=&ed=&size=M&log=0&t=BAR&v=1&g=1&evnt=1&late=1&o1=&o2=&o3=&sh=100&indicators=MFI%2814%2C255%2C100%2C39168%2C16711680%29%3BSTOSL%2814%2C3%2C16763904%2C6724095%29%3BSMA%2820%2C16711680%29&chartindicator_4_code=MFI&chartindicator_4_param_0=14&chartindicator_4_param_1=255&chartindicator_4_param_2=100&chartindicator_4_param_3=39168&chartindicator_4_param_4=16711680&chartindicator_5_code=STOSL&chartindicator_5_param_0=14&chartindicator_5_param_1=3&chartindicator_5_param_2=16763904&chartindicator_5_param_3=6724095&chartindicator_6_code=SMA&chartindicator_6_param_0=20&chartindicator_6_param_1=16711680&addindicator=&submitted=1&fpage=&txtDate=&x=13&y=12
I like the Chart of NMTI.
NMTI Daily
http://stockcharts.com/h-sc/ui?s=NMTI&p=D&yr=1&mn=0&dy=0&id=p64976928251
this just makes it even cheaper for companies to take over. its a medical company that works on the number one killer in America. Its just a matter of time bigger companies see the value an take over this cheap company and throw it back to nasdaq for a much higher price.. patience will pay off !
lol, i don't think ya missed breakfast cause this thing is toast.
i had it come up on a pincher scan.
NMT Medical, Inc. Assigns All of Its Assets for the Benefit of Creditors
liquidation of assets
Skipped breakfast and bought in today at .016 as a maniac lotto play
Sell it to someone who listens to BS -
1)NO PROCEEDS FOR COMMONS NOT SURE! MANAGEMENT MUST "PROTECT" COMMONS FROM SPECULATION, CAUTIONING THEM THAT THEY COULD NOT RECEIVE NOTHING.
BUT THAT'S THE WORST SCENARIO, ALREADY INCLUDED IN PPS. INFACT PPS DISCOUNTS ONLY THE 25% OF THE REMAINING SHELL VALUE (1M $ THE TYPICAL MARKET CAP OF A CLEAN SHELL WITHOUT DEBT, TAX CREDIT ASSETS, PERHAPS IP, VERY LOW OS...OR .0625$, WHILE CURRENT MARKET CAP IS LESS THAN 250k $!!!)
2)NO PROCEEDS (FROM ASSETS LIQUIDATION OR ASSIGNMENT) FOR COMMONS DOESN'T MEAN NO LEFT VALUE IN EQUITY! CREDITORS ARE OWED THE ASSETS, NOT THE EQUITY AND THE RIGHTS OWED TO EQUITY HOLDERS. IF SHELL R/M, OWNERS OF EQUITY WILL BENEFICIATE, NOT CREDITORS ALREADY FULLY REPAID. ASSETS MAY OUTWEIGH LIABILITIES, THIS IS N0T A FIRE SALE, BUT AN ORDERLY WIND DOWN.
Sorry, stock appears doomed, ultra high risk being pushed on all the boards except this one..... Red Flag???? I would think so.
Here is the answer to the crashing of the stock from April 19th:
The Assignment is a common law business liquidation mechanism under Massachusetts law that is an alternative to a formal bankruptcy proceeding. Under the terms of the Assignment, the Company transferred all of its assets to an assignee for orderly liquidation and distribution of the proceeds to the Company's creditors. The designated assignee for the Company is Joseph F. Finn, Jr. For creditors and other affected parties of NMT Medical, Inc. all inquiries related to this action should be addressed to Joseph F. Finn, Jr. at Finn, Warnke and Gayton, 167 Worcester Street, Suite 201, Wellesley Hills, MA 02481 (781-237-8840). Following the liquidation of the Company's assets and distribution of proceeds by the assignee, the Company does not expect that there will be any proceeds for distribution to the Company's stockholders. As part of the Assignment, the Company has terminated the employment of all of its employees.
I agree with some of your post....but there product has failed in multiple studies....so I guess the question becomes whats the value after the creditors are paid
NMTI- undervalued monster
April 22, 2011--- NMTI ( NMT Medical Inc.)
I've been watching this one for a while and finally bought it just under 2 cents today since this is, in my opinion a ridiculous price for this company...
Even though the financials are not showing it on first sight, this company has been around for long enough to prove that there is huge potential but due to the lack of responsible management team it has not been performing so well. Either way, history shows what this tiny monster is capable of and now it is the cheapest it has ever been, making it HUGE attraction to SPECULATORS and VALUE INVESTORS. This company specializes in production of machinery, associated with heart desease treatment(heart desease is number 1 killer in United States ...btw ;) ). Anyways, my DD is giving me confidence that at this point they are put to the edge where a drastic change in management and financing will take place unlocking the true potential of this medical company, allowing for further growth and development. At such a cheap price, interest will be HUGE, sending this baby to the moon. Speculation should also kick in once interest rolls around increasing the price even further, however, since it is so cheap - every cent counts for alot more than the more expensive stocks, which will further play a major role in how the MASS PSYCHOLOGY reacts to this, rather than what the financials are showing on first sight.
The gap down a couple days ago was taken by a serious player, indicating that there is a buyer waiting at the 1 cent level, giving early signs of a bottom forming. I am expecting a bounce in the next couple of days, first time might not make it to my $5 target but even a bounce up to about 50 cents would yield a 2500% return !! (current price of 2 cents a share).
The risk-reward on this one is very good since its so cheap and i am confident that this price level will switch the downtrend to upwards very soon when the Value Investors step in, backed up by daytraders and swing traders.
At such a cheap price, you can't really go wrong with it unless the euphoria takes over and you forget when to take profits and re-enter, but personally i dont see anything less than +500% return on this baby!
And this? What the hell has happened?
PD: L2 looks like utter crap.
Chart ( daily / weekly ) >>> LINK back
But hey, the news could make for a risky and ultra-cheap bottom of the bucket play ....
http://ih.advfn.com/p.php?pid=nmona&article=46270713
agreed way to undervalued.
this should be atleast 2 dollar.
Nice...$1 coming soon
Followers
|
16
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
296
|
Created
|
04/29/08
|
Type
|
Free
|
Moderators |
NMT Medical Announces First-Quarter 2008 Financial Results
Tuesday May 6, 7:30 am ET
For the first quarter of 2008, NMT reported a net loss of approximately $3.9 million, or $0.30 per share. This compares with a net loss of approximately $336,000, or $0.03 per share, for the comparable period in 2007.
27 Wormwood street
Boston, MA 02210-1625
United States - Map
Phone: 617-737-0930
Fax: 617-737-0924
Web Site: http://www.nmtmedical.com
DETAILS
Index Membership: N/A
Sector: Healthcare
Industry: Medical Instruments & Supplies
Full Time Employees: 118
BUSINESS SUMMARY
NMT Medical, Inc., a medical technology company, engages in the design, development, manufacture, and marketing of proprietary implant technologies that allow interventional cardiologists to treat cardiac structural heart disease through minimally invasive, catheter-based procedures.
Technology Overview http://www.nmtmedical.com/technology.aspx?id=206
Its products primarily include CardioSEAL, a cardiac septal repair implant device used for the repair of structural heart disease and intracardiac shunts that result in abnormal blood flow through the chambers of the heart; STARFlex, which incorporates a self-centering system that allows the implant to self-adjust to variations in the anatomy of a septal defect without deforming the septum or interfering with heart valve function; and BioSTAR, a bioabsorbable PFO implant and biological closure technology.
The company also develops BioTREK, which incorporates a unique biosynthetic material that uses the body's own regenerative capability to restore function naturally.
NMT Medical's customers include hospitals, clinics, and other healthcare centers. It markets its product CardioSEAL through its direct sales force to customers in the United States and Canada; and CardioSEAL, STARFlex, and BioSTAR directly in European markets, as well as through selected distributors in the other parts of Europe. The company was founded in 1986 and is headquartered in Boston, Massachusetts.
NMT Medical is currently investigating the potential connection between a common heart defect that allows a right to left shunt or flow of blood through a defect like a patent foramen ovale (PFO) and brain attacks such as embolic stroke, transient ischemic attacks (TIAs) and migraine headaches. A common right to left shunt can allow venous blood, unfiltered and unmanaged by the lungs, to enter the arterial circulation of the brain, possibly triggering a cerebral event or brain attack. More than 27,000 PFOs have been treated globally with NMT's minimally invasive, catheter-based implant technology. NMT Medical was founded in 1986 and is headquartered in Boston, Massachusetts.
Stroke Opportunity
PFO has been implicated as a possible risk factor of embolic stroke and TIA, for which current treatments include lifelong drug therapy or open heart surgery. NMT estimates the worldwide market for stroke- and TIA-related PFO closure procedures at 250,000 annually.
Migraine Opportunity
Medical research suggests that PFO may be a factor in certain migraine headaches. Of the 30 million migraine sufferers in America, those who experience aura and have a PFO may represent up to a 1.5 million patient subset. This represents NMT’s U.S. target market.
KEY EXECUTIVES
Mr. John Ahern , 63
Chief Exec. Officer, Pres
Mr. Richard E. Davis , 49
Chief Financial Officer, Principal Accounting Officer, Exec. VP and Sec.
Mr. Brad Ryno ,
VP of Worldwide Sales
Mr. Geoff Fournie ,
VP of Clinical Devel. for Europe
Shares
12.97 m
Float
12.6 mil
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |